Apyx Medical (NASDAQ:APYX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09), Zacks reports. Apyx Medical had a negative net margin of 37.11% and a negative return on equity of 143.12%. The business had revenue of $11.37 million for the quarter, compared to analysts' expectations of $11.69 million. Apyx Medical updated its FY 2025 guidance to EPS.
Apyx Medical Price Performance
Shares of APYX traded up $0.22 during mid-day trading on Friday, reaching $2.18. 292,299 shares of the stock traded hands, compared to its average volume of 96,807. Apyx Medical has a 1 year low of $0.76 and a 1 year high of $2.73. The firm has a fifty day moving average price of $2.03 and a 200 day moving average price of $1.53. The company has a market cap of $82.38 million, a price-to-earnings ratio of -4.84 and a beta of 1.39. The company has a current ratio of 5.45, a quick ratio of 4.64 and a debt-to-equity ratio of 3.21.
Apyx Medical Company Profile
(
Get Free Report)
Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Apyx Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apyx Medical wasn't on the list.
While Apyx Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.